Bicara Therapeutics Inc. launches FORTIFI clinical trial targeting 1L R/M HPV negative HNSCC patients

Bicara Therapeutics Inc. launches FORTIFI clinical trial targeting 1L R/M HPV negative HNSCC patients
Bicara launches FORTIFI clinical trial

Bicara Therapeutics Inc. has initiated the FORTIFI clinical trial aimed at addressing a significant unmet medical need in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC).

This specific patient population is characterized by a poor prognosis and limited durable treatment options. The company is positioning its trial to deliver new hope for patients for whom existing therapies have been insufficient. Additional resources and detailed information about the trial have been made available for those interested in learning more.

Bicara Therapeutics has previously announced deep and durable responses for the combination of ficerafusp alfa and pembrolizumab in HPV-negative HNSCC patients, according to published trial results. The company is also scheduled to present its first quarter 2026 financial results and business update on May 11 in a public webcast. These developments provide additional context for the FORTIFI trial's launch.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.